Manasi Vaidya

New York

Reporter and Editor at GlobalData

Reporter and Editor at Pharmaceutical-Technology.com

Healthcare reporter and editor @PharmaTechFocus @globaldataplc, NYU SHERP alum, past @NautilusMag @NatureMedicine Film trivia junkie.

Featured in: Favicon

globaldata.com Favicon

pharmaceutical-technology.com Favicon

clinicaltrialsarena.com Favicon

medicaldevice-network.com Favicon

msn.com

nature.com Favicon

yahoo.com (+1) Favicon

nautil.us

investmentmonitor.ai Favicon

businessandamerica.com

Articles

FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use

1 week ago | clinicaltrialsarena.com | Manasi Vaidya

US Food and Drug Administration (FDA) Commissioner Dr. Marty Makary addressed concerns about the recent cuts impacting the agency’s ability to function by emphasising that they did not affect scientific reviewers or inspectors, at an ongoing industry meeting. “I’m proud to report that we’re on track to meet all the newfound targets, and that morale is good and improving at the agency,” said Makary.
FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use

1 week ago | pharmaceutical-technology.com | Manasi Vaidya

At BIO 2025, FDA Commissioner Dr Marty Makary tried to allay industry concerns about recent cuts and outlined his agenda for the future. BIO President John Crowley [L] speaking to US FDA Commissioner Dr Marty Makary [R] at the BIO International Convention in Boston. Makary talked about his vision for the FDA, expedited programmes for drug review and the use of artificial intelligence (AI) tools.
European biotech ecosystem takes aim at changing the funding narrative

1 week ago | pharmaceutical-technology.com | Manasi Vaidya

European biotechs have historically struggled to find capital on the continent, but the funding ecosystem now aims to scale up. A panel at the 2025 BIO International Convention discuss the state of the European biotech funding ecosystem.
Trump’s first 100 days tout US-bound pharma investments amid tariff worries

1 month ago | pharmaceutical-technology.com | Manasi Vaidya

While pharma manufacturing deals in the US increased, large cuts to research and regulatory agencies increased concerns for the sector. President Donald Trump speaks during a rally at Macomb Community College on 29 April at Warren, Michigan, touting his accomplishments in the first 100 days of his presidency. Image credit: Getty Images / Scott Olson / Staff.
Podcast: What’s next for the pharma tariffs?

2 months ago | clinicaltrialsarena.com | Jenna Philpott |Abigail Beaney |Manasi Vaidya

The US government has signalled a major shift in its trade policies in recent weeks, with several announcements detailing plans for import tariffs. While President Trump has made several announcements on tariffs since he took office, things accelerated on 2 April, which was christened as ‘Liberation day’ when the administration announced reciprocal tariffs for a number of countries.
Placing the patient at the centre of the drug development paradigm

2 months ago | clinicaltrialsarena.com | Manasi Vaidya

As advocacy efforts bolster the need for patient-focused drug development, amidst regulatory encouragement, the value of listening to patients is being realised in a more actionable manner. “You can paint a fuller picture by hearing directly from patients,” said Richie Kahn, co-founder and COO of Canary Advisors. Kahn was speaking at the ongoing Outsourcing in Clinical Trials Southeast 2025 conference, being held 1–2 April in Cary, North Carolina.
How to integrate patients into clinical research with cohesive strategies

Mar 7, 2025 | clinicaltrialsarena.com | Manasi Vaidya

As patient voices get amplified across platforms, finding effective ways to further enhance participation and let patient-driven inputs drive clinical research is becoming increasingly important. An upcoming conference is set to explore this and other issues relevant to participants and sponsors who drive clinical research at pharma and biotech companies and research institutions.
Eli Lilly targets Scorpion Therapeutics to expand reach in oncology

Jan 13, 2025 | pharmaceutical-technology.com | Manasi Vaidya

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotech’s current shareholders. Eli Lilly has announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor program. Credit: Michael Vi via Shutterstock. Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets.
Trump picks vaccine sceptic RFK Jr to lead HHS in new administration

Nov 14, 2024 | clinicaltrialsarena.com | Manasi Vaidya

President-elect Donald Trump has appointed Robert F Kennedy Jr, popularly known as RFK Jr, as the secretary of the premier US health agency—the Department of Health and Human Services (HHS) — in a move that is likely to significantly impact the healthcare sector. The news, first reported by Politico around 30 minutes before the US markets closed on November 14, had an immediate negative impact on the share prices of several prominent vaccine makers including Pfizer, Sanofi and BioNTech.
Trump picks vaccine sceptic RFK Jr to lead HHS in new administration

Nov 14, 2024 | finance.yahoo.com | Manasi Vaidya

Inflation doesn't always give way in a nice, even process. In fact, since inflation started to come down after peaking in 2022, the declines have been jerky. One inflation report may show a big decline, but the next month, not so much. So it's happened this week. Both the Consumer Price Index and Producer Price Index reports showed small increases when many investors and economic experts were expecting flat results or declines.